Intellia says it has found a key clue to its gene editing safety issues

Intellia Therapeutics said it discovered a common link among the patients who faced the highest liver enzyme elevations after receiving its CRISPR gene editing treatment for ATTR amyloidosis.

Raccontata daendpoints.news